|
1
|
MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies.
|
J Exp Med
|
2013
|
1.88
|
|
2
|
Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.
|
Arch Neurol
|
2008
|
1.88
|
|
3
|
Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin.
|
J Exp Med
|
2006
|
1.69
|
|
4
|
Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity.
|
J Clin Invest
|
2006
|
1.43
|
|
5
|
Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis.
|
Proc Natl Acad Sci U S A
|
2009
|
1.31
|
|
6
|
CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation.
|
J Neuroinflammation
|
2012
|
1.29
|
|
7
|
Disease-modifying agents for multiple sclerosis: recent advances and future prospects.
|
Drugs
|
2008
|
1.25
|
|
8
|
Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
|
Arch Neurol
|
2009
|
1.24
|
|
9
|
Therapeutic decisions in multiple sclerosis: moving beyond efficacy.
|
JAMA Neurol
|
2013
|
1.16
|
|
10
|
Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.
|
CNS Drugs
|
2011
|
1.15
|
|
11
|
Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action.
|
Lancet Neurol
|
2005
|
1.10
|
|
12
|
Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.
|
Ther Adv Neurol Disord
|
2013
|
1.01
|
|
13
|
Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders.
|
J Neuroinflammation
|
2011
|
0.97
|
|
14
|
Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell response.
|
Mult Scler
|
2011
|
0.93
|
|
15
|
Antibody response in MOG(35-55) induced EAE.
|
J Neuroimmunol
|
2011
|
0.90
|
|
16
|
IgG glycan hydrolysis by EndoS inhibits experimental autoimmune encephalomyelitis.
|
J Neuroinflammation
|
2012
|
0.89
|
|
17
|
A neuropeptide in immune-mediated inflammation, Y?
|
Trends Immunol
|
2006
|
0.88
|
|
18
|
Pharmacological treatment of early multiple sclerosis.
|
Drugs
|
2008
|
0.84
|
|
19
|
Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice.
|
Curr Opin Neurol
|
2007
|
0.83
|
|
20
|
The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon?
|
CNS Neurosci Ther
|
2010
|
0.82
|
|
21
|
The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis.
|
J Neuroinflammation
|
2013
|
0.82
|
|
22
|
The value of the serum neurofilament protein heavy chain as a biomarker for peri-operative brain injury after carotid endarterectomy.
|
Neurochem Res
|
2009
|
0.81
|
|
23
|
Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model.
|
Int Immunol
|
2008
|
0.81
|
|
24
|
Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity.
|
Eur J Immunol
|
2013
|
0.80
|
|
25
|
T effectors outfox T regulators in autoimmunity.
|
Nat Med
|
2007
|
0.80
|
|
26
|
Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity.
|
J Neuroinflammation
|
2014
|
0.78
|
|
27
|
Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism.
|
Glia
|
2015
|
0.75
|